Specific inhibitors of the breast cancer resistance protein (BCRP).
about
Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein.A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1CFTR is the primary known apical glutathione transporter involved in cigarette smoke-induced adaptive responses in the lungA new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2).Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Scaffold identification of a new class of potent and selective BCRP inhibitors.Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP.Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein.Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer's disease drug candidates.The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization.Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates.Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators.Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
P2860
Q33869303-B9289E0E-BC5D-4F09-8A86-AF153A31E7F2Q34476243-5F6F4C97-7C24-419E-AF9B-4F527073584AQ34684137-465C14CE-F719-4736-BB8A-91CB8BFDCACCQ34940694-358F1ADC-C076-4094-9576-DC997DB8F689Q34977187-9D55723C-75C7-4E43-8219-8F6488C77997Q35688457-A940EA93-786D-4598-A9DA-479C23FB981AQ36020057-1136CE84-39CC-4AAA-818D-5DA5696CCCFFQ37576905-C8F54BC7-84F1-47D5-B6D0-37ED07DF4A92Q37636069-DE42C5C1-3BF8-40E8-8AC0-789DC9A1FBCDQ37853578-C7D2F526-FA22-4F32-8C9F-60D2C44E90F0Q38904223-857D19A8-57B0-46D5-8FA3-5031E743CBA1Q39233839-D94CA312-6D8B-4BA4-8C93-848F2FE55588Q39392579-EF74EC5F-44A3-41F5-9383-911BB533579CQ39503464-698780AA-4B34-4AB6-9202-17872729D2D5Q41472858-91EE712A-48E1-4E38-B9C1-8C8E6F4FD72BQ47103949-F215BEA9-AA90-4711-BEB3-2A5F5E4CB8FEQ49550379-5E1A23D6-80A9-40B6-B851-D1FDCD23118EQ51360547-B226063E-06B1-47D2-A720-E38C25146AABQ51399264-BE83C710-0139-462A-9C4B-B5BF9EC6B49BQ52908251-1C83DF03-1B85-455E-A97E-03DD79D938FF
P2860
Specific inhibitors of the breast cancer resistance protein (BCRP).
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Specific inhibitors of the breast cancer resistance protein (BCRP).
@ast
Specific inhibitors of the breast cancer resistance protein (BCRP).
@en
type
label
Specific inhibitors of the breast cancer resistance protein (BCRP).
@ast
Specific inhibitors of the breast cancer resistance protein (BCRP).
@en
prefLabel
Specific inhibitors of the breast cancer resistance protein (BCRP).
@ast
Specific inhibitors of the breast cancer resistance protein (BCRP).
@en
P2093
P356
P1433
P1476
Specific inhibitors of the breast cancer resistance protein (BCRP).
@en
P2093
Michael Wiese
Werner Klinkhammer
P304
P356
10.1002/CMDC.201000216
P577
2010-09-01T00:00:00Z